Lactobacillus + Bifidobacterium

ATC code

A07FA01

Therapeutic class

Antidiarrheal micro-organisms · Lactic acid producing organisms

Forms

powder for oral suspension

Brand names

CASENFILUS POLVO (ES)

Overall confidence

medium

Regulatory sources consulted

Approved indications

Prevention and treatment of diarrhea, including antibiotic-associated diarrhea. Adjuvant in Helicobacter pylori eradication therapy.
Symptomatic treatment of Irritable Bowel Syndrome (IBS), including abdominal pain, bloating, and altered bowel habits. · off-label
Improvement of gut dysbiosis and gastrointestinal symptoms in autism spectrum disorders (ASD). · investigational

Contraindications

Absolute

Hypersensitivity to the active substances or to any of the excipients.

Clinical warnings

Major warning · Risk of probiotic-associated sepsis in vulnerable patients (e.g., immunocompromised, critically ill, with central venous catheters). Use with extreme caution. — Clinical Practice

Drug interactions

ModerateAntibioticsJ01
Mechanism: Antibiotics can inactivate probiotic bacteria, reducing their efficacy.
Recommendation: Administer the probiotic at least 2-3 hours before or after the antibiotic dose to minimize inactivation.
Clinical Practice Guideline

Adverse events

Common (≥1%)

abdominal bloating · gas (flatulence) · mild gastrointestinal discomfort

Rare but serious

bacteremia · fungemia · sepsis

Pregnancy and lactation

FDA category: Not Assigned

Limited data in pregnancy. As a precautionary measure, its use is preferably avoided. Excretion in breast milk is unknown; evaluate risk/benefit.

Recent literature (PubMed)

Evaluation of the efficacy of probiotics as treatment in irritable bowel syndrome.
Ruiz-Sánchez C, et al. · Endocrinol Diabetes Nutr (Engl Ed) · 2024 · Relevance 5/5
Revisión que concluye que cepas individuales de Lactobacillus y Bifidobacterium, así como combinaciones, podrían ser útiles para los síntomas del Síndrome de Intestino Irritable. Bifidobacterium bifidum mostró resultados prometedores.
Microbiota in Autism Spectrum Disorder: A Systematic Review.
Lewandowska-Pietruszka Z, et al. · Int J Mol Sci · 2023 · Relevance 5/5
Revisión sistemática que encuentra que los probióticos, particularmente cepas de Lactobacillus y Bifidobacterium, muestran ser prometedores para aliviar los síntomas conductuales y gastrointestinales en niños con Trastorno del Espectro Autista (TEA).
High-fiber diet ameliorates gut microbiota, serum metabolism and emotional mood in type 2 diabetes patients.
Chen L, et al. · Front Cell Infect Microbiol · 2023 · Relevance 4/5
Estudio clínico aleatorizado que demostró que una dieta alta en fibra mejoró la homeostasis de la glucosa, el metaboloma sérico y el estado de ánimo en pacientes con diabetes tipo 2, asociado a un aumento en la abundancia de Lactobacillus y Bifidobacterium.
Effects of Probiotics and Synbiotics on Weight Loss in Subjects with Overweight or Obesity: A Systematic Review.
Álvarez-Arraño V, et al. · Nutrients · 2021 · Relevance 4/5
Revisión sistemática que sugiere que la ingesta de probióticos, especialmente cepas de Lactobacillus y Bifidobacterium, podría llevar a reducciones significativas de peso en personas con sobrepeso y obesidad.
Gut Microbiota and Colorectal Cancer: A Balance Between Risk and Protection.
Ionescu VA, et al. · Int J Mol Sci · 2025 · Relevance 3/5
Revisión sobre el papel de la microbiota en el cáncer colorrectal (CCR), destacando que bacterias protectoras como Lactobacillus y Bifidobacterium contribuyen a la homeostasis intestinal y exhiben propiedades anti-carcinogénicas, sugiriendo un potencial en la prevención o tratamiento del CCR.